Cargando…

Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis

The purpose of the present two phase 1 studies was to assess the safety, tolerability and pharmacokinetics for topical application of a novel Janus kinase (JAK) inhibitor, JTE‐052, in Japanese healthy adult male volunteers and Japanese adult patients with atopic dermatitis (AD). Additionally, explor...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakagawa, Hidemi, Nemoto, Osamu, Yamada, Hiroyuki, Nagata, Takeshi, Ninomiya, Noriko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001687/
https://www.ncbi.nlm.nih.gov/pubmed/29665062
http://dx.doi.org/10.1111/1346-8138.14322
_version_ 1783332063081922560
author Nakagawa, Hidemi
Nemoto, Osamu
Yamada, Hiroyuki
Nagata, Takeshi
Ninomiya, Noriko
author_facet Nakagawa, Hidemi
Nemoto, Osamu
Yamada, Hiroyuki
Nagata, Takeshi
Ninomiya, Noriko
author_sort Nakagawa, Hidemi
collection PubMed
description The purpose of the present two phase 1 studies was to assess the safety, tolerability and pharmacokinetics for topical application of a novel Janus kinase (JAK) inhibitor, JTE‐052, in Japanese healthy adult male volunteers and Japanese adult patients with atopic dermatitis (AD). Additionally, exploratory investigation was performed on the efficacy for disease severity and pruritus score in AD patients. In the QBX1‐1 study, the cutaneous safety of JTE‐052 ointment by a patch test and a photo patch test was assessed in an intra‐individual comparative study using placebo ointment, white petrolatum and non‐application as comparators. The study demonstrated that JTE‐052 ointment would be associated with a low potential for phototoxicity but had no potential for skin irritation or photoallergy. In the QBX1‐2 study, it was revealed that the systemic exposure to JTE‐052 in both healthy volunteers with normal skin and AD patients with inflamed skin was low in application of not only 1% but also 3% JTE‐052 ointment. JTE‐052 ointments of 1% and 3% were generally safe and well tolerated in both populations. In a repeated twice‐daily application for 7 days, the efficacy of JTE‐052 ointment to AD patients was observed with both 1% and 3% ointments in the exploratory investigations evaluated by Eczema Area and Severity Index, Investigator's Global Assessment and Numeric Rating Scale assessments. The mean scores for each assessment declined from the baseline throughout the study. These results suggest that the treatment of JTE‐052 ointment is generally safe and effective in AD patients, although further large confirmatory studies are needed.
format Online
Article
Text
id pubmed-6001687
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60016872018-06-21 Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis Nakagawa, Hidemi Nemoto, Osamu Yamada, Hiroyuki Nagata, Takeshi Ninomiya, Noriko J Dermatol Original Articles The purpose of the present two phase 1 studies was to assess the safety, tolerability and pharmacokinetics for topical application of a novel Janus kinase (JAK) inhibitor, JTE‐052, in Japanese healthy adult male volunteers and Japanese adult patients with atopic dermatitis (AD). Additionally, exploratory investigation was performed on the efficacy for disease severity and pruritus score in AD patients. In the QBX1‐1 study, the cutaneous safety of JTE‐052 ointment by a patch test and a photo patch test was assessed in an intra‐individual comparative study using placebo ointment, white petrolatum and non‐application as comparators. The study demonstrated that JTE‐052 ointment would be associated with a low potential for phototoxicity but had no potential for skin irritation or photoallergy. In the QBX1‐2 study, it was revealed that the systemic exposure to JTE‐052 in both healthy volunteers with normal skin and AD patients with inflamed skin was low in application of not only 1% but also 3% JTE‐052 ointment. JTE‐052 ointments of 1% and 3% were generally safe and well tolerated in both populations. In a repeated twice‐daily application for 7 days, the efficacy of JTE‐052 ointment to AD patients was observed with both 1% and 3% ointments in the exploratory investigations evaluated by Eczema Area and Severity Index, Investigator's Global Assessment and Numeric Rating Scale assessments. The mean scores for each assessment declined from the baseline throughout the study. These results suggest that the treatment of JTE‐052 ointment is generally safe and effective in AD patients, although further large confirmatory studies are needed. John Wiley and Sons Inc. 2018-04-17 2018-06 /pmc/articles/PMC6001687/ /pubmed/29665062 http://dx.doi.org/10.1111/1346-8138.14322 Text en © 2018 Japan Tobacco Inc. The Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Japanese Dermatological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Nakagawa, Hidemi
Nemoto, Osamu
Yamada, Hiroyuki
Nagata, Takeshi
Ninomiya, Noriko
Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
title Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
title_full Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
title_fullStr Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
title_full_unstemmed Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
title_short Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE‐052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis
title_sort phase 1 studies to assess the safety, tolerability and pharmacokinetics of jte‐052 (a novel janus kinase inhibitor) ointment in japanese healthy volunteers and patients with atopic dermatitis
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6001687/
https://www.ncbi.nlm.nih.gov/pubmed/29665062
http://dx.doi.org/10.1111/1346-8138.14322
work_keys_str_mv AT nakagawahidemi phase1studiestoassessthesafetytolerabilityandpharmacokineticsofjte052anoveljanuskinaseinhibitorointmentinjapanesehealthyvolunteersandpatientswithatopicdermatitis
AT nemotoosamu phase1studiestoassessthesafetytolerabilityandpharmacokineticsofjte052anoveljanuskinaseinhibitorointmentinjapanesehealthyvolunteersandpatientswithatopicdermatitis
AT yamadahiroyuki phase1studiestoassessthesafetytolerabilityandpharmacokineticsofjte052anoveljanuskinaseinhibitorointmentinjapanesehealthyvolunteersandpatientswithatopicdermatitis
AT nagatatakeshi phase1studiestoassessthesafetytolerabilityandpharmacokineticsofjte052anoveljanuskinaseinhibitorointmentinjapanesehealthyvolunteersandpatientswithatopicdermatitis
AT ninomiyanoriko phase1studiestoassessthesafetytolerabilityandpharmacokineticsofjte052anoveljanuskinaseinhibitorointmentinjapanesehealthyvolunteersandpatientswithatopicdermatitis